Cargando…

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach

Autosomal dominant polycystic disease (ADPKD) is the most frequent monogenic kidney disease. It causes progressive renal failure, endothelial dysfunction, and hypertension, all of which are strictly linked to oxidative stress (OxSt). Treatment with tolvaptan is known to slow the renal deterioration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigato, Matteo, Carraro, Gianni, Cirella, Irene, Dian, Silvia, Di Vico, Valentina, Stefanelli, Lucia Federica, Ravarotto, Verdiana, Bertoldi, Giovanni, Nalesso, Federico, Calò, Lorenzo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777601/ https://www.ncbi.nlm.nih.gov/pubmed/35054096 http://dx.doi.org/10.3390/jcm11020402

Ejemplares similares

Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

Pathomechanism of oxidative stress in cardiovascular-renal remodeling and therapeutic strategies
por: Ravarotto, Verdiana, et al.
Publicado: (2022)

The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study
por: Bertoldi, Giovanni, et al.
Publicado: (2022)

Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?
por: Bertoldi, Giovanni, et al.
Publicado: (2023)

Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?
por: Ravarotto, Verdiana, et al.
Publicado: (2018)

Oxidants and Cardiorenal Vascular Remodeling—Insights from Rare Genetic Tubulopathies: Bartter’s and Gitelman’s Syndromes
por: Sgarabotto, Luca, et al.
Publicado: (2023)

Calcineurin-Inhibitor-Induced Hypomagnesemia in Kidney Transplant Patients: A Monocentric Comparative Study between Sucrosomial Magnesium and Magnesium Pidolate Supplementation
por: Stefanelli, Lucia Federica, et al.
Publicado: (2023)

ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes
por: Calò, Lorenzo A., et al.
Publicado: (2021)

The Supporting Role of Combined and Sequential Extracorporeal Blood Purification Therapies in COVID-19 Patients in Intensive Care Unit
por: Nalesso, Federico, et al.
Publicado: (2022)

ROCK (RhoA/Rho Kinase) in Cardiovascular–Renal Pathophysiology: A Review of New Advancements
por: Seccia, Teresa M., et al.
Publicado: (2020)

Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients
por: Calò, Lorenzo A., et al.
Publicado: (2020)

Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?
por: Ravarotto, Verdiana, et al.
Publicado: (2018)

The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelman’s and Bartter’s Syndromes
por: Francini, Francesco, et al.
Publicado: (2021)

The Pivotal Role of Oxidative Stress in the Pathophysiology of Cardiovascular-Renal Remodeling in Kidney Disease
por: Ravarotto, Verdiana, et al.
Publicado: (2021)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Impaired ACE2 glycosylation and protease activity lowers COVID‐19 susceptibility in Gitelman's and Bartter's syndromes
por: Bertoldi, Giovanni, et al.
Publicado: (2021)

Angiotensin II, RAS Activation, and RAS Blockers in COVID-19: Unambiguous Evidence
por: Calò, Lorenzo A., et al.
Publicado: (2022)

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

The Assessment of Renal Functional Reserve in β-Thalassemia Major Patients by an Innovative Ultrasound and Doppler Technique: A Pilot Study
por: Nalesso, Federico, et al.
Publicado: (2022)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

The patient safety in extracorporeal blood purification treatments of critical patients
por: Nalesso, Federico, et al.
Publicado: (2022)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
por: Todorova, Polina, et al.
Publicado: (2023)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection
por: Calò, Lorenzo A., et al.
Publicado: (2022)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
por: Barnawi, Rashid A, et al.
Publicado: (2018)

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study
por: Schirutschke, Holger, et al.
Publicado: (2021)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach
por: Innico, Georgie, et al.
Publicado: (2021)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Slow Continuous Ultrafiltration in Regional Citrate Anticoagulation Performed with a Standard Fluid Infusion Central Venous Catheter in Intensive Care Unit for Fluid Overload in Acute on Chronic Heart Failure: A Case Report
por: Nalesso, Federico, et al.
Publicado: (2023)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nt84m3936d2ht0mf7tmkhjna4c